RxDoctor Payments DataLook up a doctor →

Ashley Bell

Family · Knoxville, TNNPI 1114562782

Payments from drug & device makers

$22,254in general payments, 2019–2025

Across 1,153 payments — averaging $19.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$2K
  • AstraZeneca$2K
  • Incyte Corporation$1K
  • Daiichi Sankyo Inc.$1K
  • Johnson & Johnson$1K
  • E.r. Squibb & Sons, L.L.C.$1K
  • plus $14K from 54 others

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novartis71$2,385
AstraZeneca(2 entities)82$1,603
Incyte Corporation57$1,206
Daiichi Sankyo Inc.62$1,164
Johnson & Johnson56$1,119
E.r. Squibb & Sons, L.L.C.88$1,036
Pfizer56$979
Bristol Myers Squibb57$848
Merck39$775
Seagen Inc.32$764
Genentech USA, Inc.43$713
Sanofi34$618
Astellas Pharma US Inc32$599
Lilly USA, LLC38$578
GSK29$500
Bayer26$466
Gilead(2 entities)26$438
Takeda Pharmaceuticals U.S.A., Inc.20$420
Eisai Inc.24$415
Myriad Genetic Laboratories, Inc.17$339
Amgen20$335
Exelixis Inc.14$326
Pharmacyclics LLC, An Abbvie Company18$280
Beigene USA, Inc.10$275
AbbVie15$273
Regeneron Healthcare Solutions, Inc.13$273
AVEO Pharmaceuticals, Inc.8$239
Array Biopharma Inc14$206
Sobi, Inc10$193
Mirati Therapeutics, Inc.7$186
EMD Serono, Inc.10$175
Karyopharm Therapeutics Inc.7$174
Ipsen Biopharmaceuticals, Inc8$161
Rigel Pharmaceuticals, Inc.9$147
Morphosys, US Inc.6$144
Tersera Therapeutics LLC8$142
Pharmacosmos Therapeutics Inc.7$125
Taiho Oncology, Inc.6$118
G1 Therapeutics, Inc.5$102
Sanofi-aventis U.S. LLC1$100
Coherus Oncology, Inc.4$89
Stemline Therapeutics Inc.4$88
Pharmaessentia USA Corporation4$87
Beone Medicines USA, Inc.4$81
Springworks Therapeutics, Inc.2$79
Puma Biotechnology, Inc.4$75
Boehringer Ingelheim4$74
Deciphera Pharmaceuticals Inc.3$71
TG Therapeutics, Inc.3$61
Jazz Pharmaceuticals Inc.3$56
Blueprint Medicines Corporation2$47
Acrotech Biopharma Inc.3$43
Epizyme, Inc.3$41
Genmab U.S., Inc.2$41
Legend Biotech USA Inc.1$38
Apellis Pharmaceuticals, Inc.2$37
Novocure Inc.2$36
Clovis Oncology, Inc.3$33
Acceleron Pharma, Inc.2$33
Myovant Sciences Inc.2$30

How this compares

$22,254 in reported general payments places this provider in the 95th percentile of 6,706 family providers in Tennessee.

See all family providers in Tennessee →

Medicare billing

Part B allowed, 2024
$84,057
Medicare patients
109
Services billed
6,840

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other family in Knoxville

See the full list for Tennessee →

Where these figures come from

Is this you, or does something look wrong? →